GTS Securities’s Syndax Pharmaceuticals SNDX Stock Holding History

GTS Securities’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-42,800	Closed	-$621K	–	4393
2023 Q3	$621K	Buy	+42,800	New	+$810K	﹤0.01%	2408

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GTS Securities's SNDX Position: Q4 2023 in Review

GTS Securities sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 14,403 shares — an estimated $209K sold.

GTS Securities first reported a position in SNDX in Q3 2023 and held it in 1 quarter. The position peaked at $209K in Q3 2023. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

GTS Securities reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 14,403 Syndax Pharmaceuticals shares in Q4 2023, an estimated $209K.
GTS Securities first reported a position in Syndax Pharmaceuticals in Q3 2023 and held it in 1 quarter.
GTS Securities's Syndax Pharmaceuticals position peaked at $209K in Q3 2023.
177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.